Physician profile
Timothy Obrien
NPI 1487728937
$495.35
in general payments reported to CMS, 2019-2025
16 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.03 · 2020: $86.04 · 2024: $40.52 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.03 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.90 | 2025 | |
| Astellas Pharma US INC | $65.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.65 | 2019-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $54.61 | 2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $48.85 | 2019-2025 | Jakafi, Niktimvo |
| Emd Serono, INC. | $38.21 | 2025 | |
| Eisai INC. | $23.50 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $22.90 | 2020 | |
| Karyopharm Therapeutics INC. | $21.73 | 2020 | |
| Daiichi Sankyo INC. | $20.78 | 2024 | Enhertu |
| Pfizer INC. | $19.74 | 2024 | |
| Puma Biotechnology, INC. | $19.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.80 | 2025 | Opdivo |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.